Roche drops Alzheimher drug trials after setback [Reuters (UK)]
Last ac immune sa earnings: 11/13 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations: acimmune.com/en/investors
Roche drops Alzheimer drug trials after setback | Reuters 1 Min Read ZURICH (Reuters) - Roche Holding will halt two late-stage clinical trials of its crenezumab drug in early Alzheimer’s disease after an interim analysis indicated it was unlikely to hits its primary goal, the Swiss drugmaker said on Wednesday. Roche was working on the product with AC Immune. Roche said an Alzheimer’s Prevention Initiative (API) study of crenezumab in familial Alzheimer’s disease continued and that it remained committed to ongoing clinical studies in Alzheimer’s disease, including phase-III trials with gantenerumab and a phase-II anti-tau trial. AC Immune Chief Executive Andrea Pfeifer said the company was “extremely disappointed” by the news. “We continue to be optimistic about the potential future of crenezumab as we await the outcome of the Colombian API study to prevent AD symptoms in patients with familial AD to see if the antibody treatment may provide disease-modifying effects in patients with e
[Read more]
| Impact snapshot | Event time: | ACIU | ||||
|---|---|---|---|---|---|---|
|
Last Price
|
Price Change
|
Price Change %
|
Volume Shares
|
Max Up
|
Max Down
|
Volume Ratio
%
|
Performance comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last price | ||
| VWAP | ||
|
High:
|
Max up |
High:
|
|
Low:
|
Max down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event Day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance Since Event
Time and Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
SIGN UP TODAY
Opt-in for
ACIU alerts
ACIU alerts
from News Quantified
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ACIU alerts
High impacting AC Immune SA news events
Weekly update
A roundup of the hottest topics
ACIU
News
- AC Immune Appoints Experienced Biotech and Investment Executive Dr. Alan Colowick to Board of DirectorsGlobeNewswire
- AC Immune Hosts Investor Webinar Highlighting the Power of its Morphomer™ Platform to Enable Precision Medicine for Neurodegenerative DiseaseGlobeNewswire
- AC Immune SA (<a href="https://www.marketbeat.com/stocks/NASDAQ/ACIU/price-target/">NASDAQ: ACIU</a>) had its price target raised by analysts at HC Wainwright from $11.00 to $16.00. They now have a "buy" rating on the stock.MarketBeat
- AC Immune to Host Webinar Highlighting its Innovative Morphomer™ Technology Platform and PipelineGlobeNewswire
- AC Immune SA (<a href="https://www.marketbeat.com/stocks/NASDAQ/ACIU/price-target/">NASDAQ: ACIU</a>) had its price target raised by analysts at HC Wainwright from $11.00 to $16.00. They now have a "buy" rating on the stock.MarketBeat
- More
ACIU
SEC Filings
- 3/31/21 - Form 6-K
- 3/23/21 - Form 6-K
- 3/23/21 - Form 20-F
- ACIU's page on the SEC website
- More